Literature DB >> 7571387

Cephalothin and cefazolin in vitro antibacterial activity and pharmacokinetics in dogs.

S W Petersen1, E Rosin.   

Abstract

The periods of time that cephalothin and cefazolin serum concentration remained above minimum inhibitory concentration (MIC) for beta hemolytic, coagulase positive staphylococcal, and Escherichia coli clinical isolates were compared. Cephalothin and cefazolin were similarly very effective in vitro against staphylococcal isolates, with an MIC90 of 0.12 microgram/mL and 0.25 microgram/mL, respectively. In contrast, cefazolin was more effective than cephalothin against E coli isolates; the cefazolin MIC90 for E coli was 16 micrograms/mL and for cephalothin 64 micrograms/mL. Cefazolin (20 mg/kg intravenously [i.v.]) serum concentration remained more than MIC90 for E coli isolates significantly longer than serum concentration of cephalothin (40 mg/kg i.v.) (P < .001).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571387     DOI: 10.1111/j.1532-950x.1995.tb01341.x

Source DB:  PubMed          Journal:  Vet Surg        ISSN: 0161-3499            Impact factor:   1.495


  3 in total

1.  Physiological modeling for indirect evaluation of drug tissular pharmacokinetics under non-steady-state conditions: an example of antimicrobial prophylaxis during liver surgery.

Authors:  Franck Lagneau; Jean Marty; Pascale Beyne; Michel Tod
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

2.  Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination.

Authors:  Petra Cagnardi; Federica Di Cesare; Pierre-Louis Toutain; Alain Bousquet-Mélou; Giuliano Ravasio; Roberto Villa
Journal:  Front Pharmacol       Date:  2018-10-09       Impact factor: 5.810

3.  Evaluation of Acquired Antibiotic Resistance in Escherichia coli Exposed to Long-Term Low-Shear Modeled Microgravity and Background Antibiotic Exposure.

Authors:  Madhan R Tirumalai; Fathi Karouia; Quyen Tran; Victor G Stepanov; Rebekah J Bruce; C Mark Ott; Duane L Pierson; George E Fox
Journal:  mBio       Date:  2019-01-15       Impact factor: 7.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.